– USA, NC – BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Steven Galson (M.D., MPH) to its board of directors.
“Through his R&D leadership role at Amgen and his experience as the director of CDER at FDA, Steve has seen first-hand what it takes for companies to successfully develop and commercialize a broad portfolio of medicines that meet unmet needs for patients, and we are very pleased to add his world-class expertise to the BioCryst board,” said Board Chairman, Robert Ingram.
About Dr. Steven Galson
Most recently, Dr. Galson served as SVP, research and development at Amgen. Before joining Amgen in 2010, where he also led regulatory affairs, Dr. Galson spent more than 20 years in public service roles across the U.S. Department of Health and Human Services, Department of Energy, Environmental Protection Agency, and Centers for Disease Control and Prevention. From 2001 to 2007, Dr. Galson progressed from deputy director to acting director, to director of CDER at the FDA. From 2007 to 2009 he served as acting surgeon general of the United States.
“It has been impressive to watch as an industry observer how rapidly BioCryst has invented and developed multiple novel, oral medicines for rare diseases that act against such challenging drug targets. I am excited to join the board at this transformative time for the company, with a successful commercial launch of ORLADEYO® underway, BCX9930 advancing across many indications and a prolific R&D team continuing to develop new medicines for patients with rare diseases,” said Dr. Galson.
Dr. Galson received a B.S. in biochemistry from the State University of New York at Stony Brook, an M.D. from the Mt. Sinai School of Medicine, and a master’s in public health from the Harvard School of Public Health.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO is approved in the United States, the European Union, Japan, and the United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, and Korea. Post-marketing commitments for RAPIVAB are ongoing.
For more information: https://www.biocryst.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
